1. Home
  2. SNTI vs KNRX Comparison

SNTI vs KNRX Comparison

Compare SNTI & KNRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Senti Biosciences Inc.

SNTI

Senti Biosciences Inc.

N/A

Current Price

$0.33

Market Cap

10.4M

Sector

Health Care

ML Signal

N/A

Logo KNOREX LTD. Class A Ordinary Shares

KNRX

KNOREX LTD. Class A Ordinary Shares

N/A

Current Price

$0.28

Market Cap

10.9M

Sector

Technology

ML Signal

N/A

Company Overview

Basic Information
Metric
SNTI
KNRX
Founded
2016
2009
Country
United States
Singapore
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Computer Software: Programming Data Processing
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
10.4M
10.9M
IPO Year
2021
2023

Fundamental Metrics

Financial Performance
Metric
SNTI
KNRX
Price
$0.33
$0.28
Analyst Decision
Buy
Analyst Count
2
0
Target Price
★ $13.50
N/A
AVG Volume (30 Days)
306.8K
★ 14.0M
Earning Date
11-12-2026
10-06-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 77.31
N/A
EPS
N/A
★ N/A
Revenue
N/A
N/A
Revenue This Year
$127.27
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
★ N/A
52 Week Low
$0.29
$0.28
52 Week High
$2.88
$3.45

Technical Indicators

Market Signals
Indicator
SNTI
KNRX
Relative Strength Index (RSI) 39.33 46.81
Support Level $0.29 N/A
Resistance Level $0.37 $0.55
Average True Range (ATR) 0.03 0.14
MACD 0.01 0.00
Stochastic Oscillator 24.37 0.91

Price Performance

Historical Comparison
SNTI
KNRX

About SNTI Senti Biosciences Inc.

Senti Biosciences Holdings Inc, formerly known as Senti Biosciences Inc, is a clinical-stage biotechnology company developing cell and gene therapies using its gene circuit platform for patients with incurable diseases. Its gene circuits, created from proprietary DNA sequences, are designed to reprogram cells to sense, compute, and respond to cellular environments. Its product candidates are to kill cancer cells, spare healthy cells, increase specificity, and control drug expression. Its candidate, SENTI-202, is a logic-gated off-the-shelf CAR-NK cell therapy for blood cancers, currently in a Phase 1 clinical trial in the United States and Australia for relapsed or refractory hematological malignancies, including Acute Myeloid Leukemia (AML).

About KNRX KNOREX LTD. Class A Ordinary Shares

Knorex Ltd is a B2B technology company providing programmatic advertising products and solutions to marketers to streamline and automate their advertising and marketing workflows. The company's product, Knorex XPOSM, is a self-service, enterprise-grade cloud platform with a suite of advertising management and execution (AMX) applications.

Share on Social Networks: